AYUSH healthcare advertising compliance India
Ayurveda, wellness, yoga and panchakarma advertising sits under one of the strictest claim regimes in Indian healthcare marketing — a base statute that bans disease-cure claims outright, a Ministry of AYUSH guidance layer, and state AYUSH boards that enforce the same rules with real variance in practice. This advisory maps what the regulator requires, where brands actually go wrong, and the audit-and-remediation framework ICG runs on every AYUSH client before a single rupee of ad spend goes live.
TL;DR
- The Drugs and Magic Remedies Act, 1954 bans advertised cure, prevention, or diagnosis claims for a named disease schedule (diabetes, cancer, sexual disorders and more) — this applies to ayurveda exactly as it applies to allopathy.
- Ministry of AYUSH guidance and state AYUSH boards add a second layer on top of the base statute, and enforcement posture genuinely differs state to state — a claim tolerated in one state's practical review is not automatically safe in another.
- An ayurvedic product sold as a medicine needs a valid drug licence, and advertised benefits must stay inside what that licence's approved indications actually cover.
- Panchakarma outcome claims, wellness-vs-medical claim boundaries, and testimonial language are the three places ICG sees the most repeat violations across ayurveda and yoga clients.
- ICG's retainers start from Rs 20,000/month, custom-scoped per engagement, and run as ongoing monitoring through the Search Intelligence Engine — not a one-time audit that goes stale the day copy changes.
What the regulator actually requires in 2026
The single most important thing to understand about AYUSH advertising compliance is that it does not start with the Ministry of AYUSH. It starts with the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954, a central statute that predates the AYUSH ministry itself and applies to every system of medicine equally — allopathic, ayurvedic, homeopathic, unani, or siddha. The Act carries a schedule of diseases and conditions for which no advertisement, in any medium, may claim to cure, prevent, diagnose, or otherwise treat. Diabetes, cancer, and several sexual and reproductive conditions sit on this schedule, along with a number of others. This is a blanket prohibition — it does not matter whether the product is a registered ayurvedic formulation, a general wellness supplement, or a yoga programme. If the advertisement names a scheduled condition and claims a therapeutic outcome against it, the advertisement itself is the violation, independent of whether the underlying product actually works.
On top of this base layer sits Ministry of AYUSH guidance, which periodically issues advisories on misleading advertisement, on unproven claims, and on the specific practice of clinics and manufacturers publishing patient testimonials that imply disease cure. These advisories don't replace the DMRA — they interpret and extend it for the AYUSH sector specifically, and they're the layer most likely to be updated as digital advertising formats (search ads, social ads, influencer content) create new surfaces the original 1954 statute never anticipated.
The third layer, and the one most brands underestimate, is the state AYUSH board. Ayurveda, yoga, and naturopathy practitioner registration and clinic licensing run through state-level AYUSH directorates, and while the underlying law is national, the practical enforcement posture — how aggressively a state board pursues advertisement complaints, how it interprets grey-area panchakarma protocol claims, how quickly it acts once a complaint lands — varies meaningfully by state. A wellness brand operating across five states cannot assume that copy cleared informally in one state carries the same risk profile in another; ICG treats each state's board posture as a distinct compliance overlay, not a footnote to the central rule.
Finally, any ayurvedic formulation sold and marketed as a medicine — not a general wellness product — requires a valid manufacturing licence under the Drugs and Cosmetics Act as applied to ayurvedic drugs, and the advertised claims have to stay within the indications that licence actually approves. This is the drug-licence-to-advertising linkage that trips up manufacturers most often: a product licensed for "digestive support" cannot be advertised for "liver detoxification" just because the formulation happens to contain ingredients that plausibly support both — the advertising claim has to match the licensed indication, not the manufacturer's belief about what the product does.
Common violations we see
Across ayurveda, wellness, yoga, and panchakarma clients, the violations ICG's audits catch cluster into a small number of repeat patterns. None of these are exotic — they're the same handful of mistakes made differently by different brands, which is precisely why a checklist-based audit catches them faster than a one-off legal review.
- Named-disease cure language. An anonymised ayurveda manufacturer's product page advertised "natural diabetes reversal" for a formulation licensed under a general metabolic-support indication. Diabetes sits on the DMRA schedule; the claim was a direct violation regardless of the product's actual licence, and the fix required removing the disease name entirely rather than softening the wording.
- Panchakarma outcome guarantees. An anonymised panchakarma centre's ad copy promised "complete detoxification in 7 days, guaranteed results." Panchakarma is a therapeutic protocol, not a packaged product, but outcome-guarantee language attaches the same way — the fix replaced the guarantee with protocol description (duration, therapy sequence, practitioner qualification) and dropped every promised-outcome phrase.
- Testimonials implying cure. An anonymised wellness clinic ran patient video testimonials describing "my arthritis is completely gone" on its ad landing page. A testimonial doesn't exempt the advertisement from the same disease-cure restriction that applies to the advertiser's own copy — the fix kept the testimonial format but re-recorded content around general wellbeing and experience rather than named-condition resolution.
- Drug-licence-to-claim mismatch. An anonymised ayurvedic supplement brand's packaging carried a general-wellness licence, but its digital ad copy claimed specific organ-detoxification benefits the licence didn't cover. The fix required either narrowing the ad claims to the licensed indication or pursuing a licence amendment before continuing the campaign — ICG does not advise running ahead of the licence and correcting later.
- Cross-state copy reuse without a state-board check. An anonymised multi-city yoga and wellness chain used identical ad copy across eight states without checking each state AYUSH board's practical enforcement posture on panchakarma and outcome-adjacent phrasing — copy that drew no complaints in one state drew a formal notice in another. The fix introduced a state-tagged review pass before any copy went live in a new state, not just at brand launch.
- Yoga programme disease-management claims. An anonymised yoga studio advertised a programme as managing high blood pressure and diabetes through specific asana sequences. Yoga instruction itself isn't a licensed drug, but the DMRA's disease-schedule restriction applies to the claim regardless of the delivery modality — the fix reframed the programme around general fitness and stress-management language.
ICG's audit + remediation framework
ICG's AYUSH compliance work runs as a five-step framework, not a single legal opinion delivered once and filed away. The first step is a claim inventory — every piece of live copy across the website, ad accounts, social channels, and packaging is catalogued against the DMRA disease schedule, the licensed indications on file for each product, and any state-specific overlay relevant to where the brand operates. This step alone typically surfaces the majority of violations, because most non-compliant claims are not deliberate — they're inherited from an earlier brand voice, a copywriter unfamiliar with the schedule, or a product team's internal shorthand that made it into public copy unchanged.
The second step is severity triage. Not every flagged claim carries the same exposure — a named-disease cure claim on a high-traffic landing page is a different priority than an ambiguous wellness phrase buried on an old blog post. ICG ranks every finding by regulatory exposure (does it name a scheduled disease directly, or only imply one) and commercial exposure (how much traffic and spend currently runs against the claim), so remediation effort goes where risk concentrates first.
The third step is rewrite and licence reconciliation — every flagged claim is either rewritten to stay inside the wellness-not-medical boundary, or, where the underlying licence genuinely supports a stronger claim than the copy currently uses, the claim is brought up to what the licence actually allows rather than left conservative for no reason. This two-directional check matters: compliance work isn't only about removing claims, it's about making sure the brand isn't under-claiming relative to what it's actually licensed and entitled to say.
The fourth step is state-board mapping for any brand operating across more than one state — a documented note on each state's practical enforcement posture, so the remediation isn't generic but specifically accounts for where the brand's real regulatory exposure sits state by state. The fifth and final step is handoff into ongoing monitoring, because a compliance audit that ends the day the report is delivered is only useful until the next copywriter, agency, or founder edits a page six months later — which is precisely the gap ICG's retainer structure and Search Intelligence Engine integration are built to close.
What clean copy looks like
"Reverse your diabetes naturally in 90 days — trusted by thousands of patients across India."
"Ayurvedic wellness programme for metabolic health, formulated with AYUSH-registered practitioners. Speak to our team about your health goals."
The rewrite drops the named disease (diabetes, on the DMRA schedule), the outcome guarantee ("in 90 days"), and the unverifiable social-proof claim ("trusted by thousands"), replacing all three with a wellness framing and a credential-based trust signal that carries no disease-schedule exposure.
"Complete detoxification guaranteed in one 7-day panchakarma protocol — permanent results."
"A 7-day panchakarma protocol combining abhyanga, swedana and basti therapies, delivered by our registered practitioners. Book a consultation to discuss what the protocol involves."
The rewrite removes the outcome guarantee and the "permanent results" claim entirely and replaces them with a factual description of the protocol's components — information a prospective client actually wants, delivered without a promise that can't be substantiated.
"Our yoga therapy programme cures high blood pressure and manages diabetes without medication."
"A structured yoga and breathwork programme designed to support cardiovascular fitness and stress management, taught by certified instructors."
"Cures" and "manages diabetes without medication" both name scheduled conditions and claim treatment outcomes; the rewrite reframes entirely around fitness and stress support, which communicates the same underlying benefit to a prospective client without the disease-schedule exposure.
Ongoing retainer support
A one-time audit report solves the problems that exist on the day it's delivered and nothing after. AYUSH brands ship new landing pages, new ad creative, and new social content on a weekly cadence, and every one of those is a fresh opportunity for a disease-schedule claim, an outcome guarantee, or a testimonial that drifts back into non-compliant territory — often written by someone on the internal team who was never handed the original audit findings. ICG's retainer engagements exist to close that gap rather than leave it open between annual reviews.
On a retainer, ICG runs a recurring review cycle against every live page, ad account, and social channel the client operates, flags new or drifted claim language the same way the original audit would, and delivers rewrites on a documented turnaround rather than an open-ended queue. State-board overlays are re-checked whenever a client expands into a new state or region, and drug-licence linkage is re-verified whenever a product's formulation, packaging, or licensed indication changes — a genuinely common trigger for compliance drift that internal teams rarely think to flag proactively.
Retainer clients also get a documented review trail for every claim currently live — which matters if a state AYUSH board or a competitor complaint ever questions a specific piece of copy, because the answer is a dated record of when the claim was reviewed and against what standard, not a scramble to reconstruct history after the fact. This is the same operating principle ICG applies across every compliance vertical it works in: the goal isn't a single clean snapshot, it's a claim inventory that stays clean as the business keeps shipping new content.
How this integrates with the Trifecta
AYUSH compliance advisory doesn't sit apart from ICG's core growth work — it runs underneath it. The Search Intelligence Engine, the middle pillar of ICG's Search Intelligence Trifecta, is what makes ongoing monitoring practical rather than manual: instead of a compliance team re-reading every page by hand every quarter, SIE tracks published claim language across the domain on a recurring schedule and surfaces anything that has drifted from the last reviewed baseline, whether that drift came from an internal team edit, a new ad batch, or a syndicated content piece picked up from elsewhere.
Angryturtle, ICG's GBP and local-visibility product, feeds into the same monitoring loop for any AYUSH brand running multi-location clinics — a Google Business Profile post or a review response is public advertising copy just as much as a webpage is, and it's frequently the surface where compliance drift first appears because it's the easiest one for a local branch manager to edit without any review step at all. YODA, the YouTube-focused pillar, applies the same claim-discipline lens to video content and video descriptions, which carry the same DMRA exposure as written copy but are far more often overlooked because they're treated as marketing rather than as advertisement text subject to review.
For an AYUSH client, the practical result is one compliance standard applied consistently across web pages, ads, GBP posts, and video content, monitored on a recurring cycle rather than reviewed once at onboarding and left to drift — the same claim-discipline framework this page describes, running continuously rather than as a single point-in-time engagement.
Pricing
Retainers from Rs 20,000/month · Custom-scoped per engagement.
Book a free diagnostic to scope your AYUSH compliance engagement →
What an engagement actually costs
ICG does not run a fixed tier structure for AYUSH compliance work, because the actual scope varies far too much brand to brand to price sensibly with a one-size menu. A single-clinic ayurveda practice with one website and no paid media has a fundamentally different claim surface than a multi-state panchakarma chain running paid ads across six cities with its own manufacturing licence to reconcile. What stays constant is the starting point: retainers from Rs 20,000/month, custom-scoped per engagement, with the exact scope — how many pages, how many states, how many channels, how frequently the review cycle runs — set during the initial diagnostic conversation rather than assumed in advance.
A typical scoping conversation covers how many product lines and states the brand operates in, whether the brand runs paid media that needs pre-push review versus only owned content that needs periodic review, and whether a drug-licence reconciliation is needed alongside the advertising claim audit. Retainers from Rs 20,000/month, custom-scoped per engagement is the floor for the smallest single-location, owned-content-only engagements; multi-state, multi-channel, paid-media-inclusive retainers scope upward from there based on the review cadence and channel count the brand actually needs.
The initial audit that establishes the baseline claim inventory is scoped and quoted separately from the ongoing retainer, because a brand's first engagement with ICG is almost always the audit — the retainer conversation happens once both sides can see the actual size of the claim surface uncovered. Retainers from Rs 20,000/month, custom-scoped per engagement remains the standing offer regardless of which stage a client starts at.
Who this is for
This advisory is built for ayurveda manufacturers and clinics, wellness and panchakarma centres, yoga studios and instructor networks, and any AYUSH-adjacent brand running a website, paid ads, or a Google Business Profile presence in India. It fits brands operating in a single state as well as multi-state chains that need a state-board-aware review rather than a generic national-only pass, and it fits both brands who have never had a formal compliance audit and brands who had one years ago and have shipped dozens of new pages and ad batches since.
It is not built for patient-facing individual medical advice, and it does not extend to clinical or manufacturing quality standards — ICG's scope is advertising and marketing claim compliance specifically, not product formulation, GMP certification, or clinical trial design. Brands looking for that adjacent work should engage the relevant technical or regulatory-affairs specialist directly; ICG's advisory picks up once the product exists and the question becomes what can be said about it publicly.
Claim discipline that holds up across every state board
ICG's audit-and-remediation framework runs on every AYUSH client before spend goes live, and stays running through retainer monitoring after. Talk to us about your product lines and states.
Frequently asked questions
What is the core law behind AYUSH advertising restrictions?
The Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 is the anchor statute — it lists specific diseases and conditions (a schedule that includes diabetes, cancer, sexual disorders, and several others) for which no advertisement may claim a cure, prevention, or diagnosis, regardless of whether the product is allopathic, ayurvedic, or any other AYUSH system. Ministry of AYUSH guidance and state AYUSH board rules sit on top of this base layer, not instead of it.
Does every state AYUSH board apply the same rules?
No. The base DMRA schedule and central Ministry of AYUSH advisories apply nationwide, but individual state AYUSH directorates and state licensing authorities vary in how strictly they enforce advertisement pre-approval, how they interpret panchakarma protocol claims, and how quickly they act on complaints. A campaign compliant in one state's practical enforcement posture is not automatically safe to run unchanged in another.
Can an ayurveda brand claim to treat or manage a named disease?
Not if the disease appears on the DMRA schedule — diabetes, cancer, and several other named conditions cannot be advertised as curable, treatable, or preventable by any product or system, ayurvedic or otherwise. Wellness, general health support, and named-ingredient benefit language are permitted where a disease-cure claim is not.
Is a drug licence required before advertising an ayurvedic product?
Yes, for any formulation sold as a medicine. An ayurvedic product manufactured and marketed as a drug requires a valid manufacturing licence under the Drugs and Cosmetics Act read with AYUSH-specific rules, and the advertised claims must stay within what that licence's approved indications actually cover — advertising a benefit the licence does not list is a separate violation from the DMRA disease-schedule issue.
What is a panchakarma protocol claim and why is it treated carefully?
A panchakarma protocol claim is any statement about the outcome of a panchakarma therapy sequence — detoxification percentages, named-disease reversal, or guaranteed results from a specific number of sessions. Because panchakarma is a therapeutic protocol rather than a packaged product, outcome claims around it are reviewed against both the DMRA disease schedule and general unsubstantiated-efficacy rules, and guaranteed-outcome language is removed regardless of how the therapy is described elsewhere.
Are testimonials allowed in AYUSH advertising?
Patient testimonials describing disease cure or dramatic before-after outcomes carry the same restriction as a direct advertiser claim — a testimonial does not exempt the advertisement from the DMRA schedule or from ASCI's substantiation requirement. General satisfaction or experience-based testimonials that avoid named-disease outcome language are lower risk but still reviewed.
What is the difference between a wellness claim and a medical claim in AYUSH marketing?
A wellness claim describes general support — energy, balance, digestion support, stress management — without naming a disease or promising a cure. A medical claim names a specific condition and asserts treatment, cure, prevention, or diagnosis. AYUSH advertising compliance work is largely the discipline of keeping copy on the wellness side of that line while still communicating enough specificity to convert.
Does yoga instruction advertising fall under the same rules as ayurveda product advertising?
Yoga instruction itself is not a drug and is not licensed the same way an ayurvedic formulation is, but yoga-adjacent advertising that claims to cure or manage a named disease through a yoga programme still falls under the DMRA schedule's general prohibition, because the Act restricts the claim regardless of the modality used to deliver it.
How does ICG monitor AYUSH compliance on an ongoing basis rather than a one-time audit?
ICG's Search Intelligence Engine tracks published pages, ad copy, and landing-page claims on a recurring schedule and flags any new or drifted claim language against the same checklist used in the initial audit, so a page edited by an internal team member six months after launch is caught the same way a launch-day draft would be.
What does ICG charge for AYUSH advertising compliance work?
Retainers from Rs 20,000/month, custom-scoped per engagement based on how many product lines, states, and channels need ongoing review.
